Purpose: To compare the motility and complication rates of porous and nonporous implants after enucleation surgery.
The American Academy of Ophthalmology prepares Ophthalmic Technology Assessments to evaluate new and existing procedures, drugs, and diagnostic and screening tests. The goal of an Ophthalmic Technology Assessment is to review systematically the available research for clinical efficacy, effectiveness, and safety. After review by members of the Ophthalmic Technology Assessment Committee, other Academy committees, relevant subspecialty societies, and legal counsel, assessments are submitted to the Academy's Board of Trustees for consideration as official Academy statements. The purpose of this assessment is to review the published literature to compare motility and complication rates of porous and nonporous implants after enucleation surgery.
Background
Enucleation may be performed in settings of refractory pain, intraocular malignancy, infection, cosmetic deformity, and severe trauma. After removal of the globe, implants often are placed to restore the volume of the orbit, to facilitate motility, and to improve the appearance of the socket. Multiple types of orbital implants that have been designed for the anophthalmic socket generally are used to achieve these goals. Traditional nonporous implants have consisted of glass, acrylic, silicone, and polymethyl methacrylate (PMMA). Porous implants made from hydroxyapatite, polyethylene, and aluminum oxide are now commonly used. 1 Theoretically, the porous nature of these implants facilitates fibrovascular ingrowth to ensure their stability and to decrease migration and extrusion; placement of a coupling peg also enhances motility. 2 Some surgeons believe that the presence of a rough, porous surface within the socket may lead to tissue degradation and an increased risk of exposure; thus, they favor wrapped or polymercoated implants.
Despite the theoretical advantages of porous implants, the optimal choice of an orbital implant after enucleation has not been determined conclusively. Previous studies have not documented a difference in implant motility or prosthetic motility between nonpegged porous enucleation implants and nonporous spheres. 3 In 2003, Custer et al 2 presented a report for the Ophthalmic Technology Assessment Committee Oculoplastic Panel of the American Academy of Ophthalmology in which the authors noted a wide range of complication rates after enucleation. This study was undertaken to update that original investigation, with the intent of assessing the existing literature regarding outcomes from the use of a variety of implants in the setting of enucleation.
Question for Assessment
The focus of this assessment is to address the following question: How do the motility and complication rates of porous and nonporous implants after enucleation surgery compare?
Description of Evidence
Literature searches of the PubMed and Cochrane Library databases were performed last in February 2017. The searches were limited to literature from 2003 through 2017 in the English language and with abstracts. The original assessment on this topic was published in 2003, and the search strategy for the current assessment was designed to identify new studies that have been reported since that date. Search terms included eye, enucleation, orbital implant, orbit, and surgery. Acceptable study designs included randomized controlled trials, nonrandomized comparative trials, cohort studies, case-control studies, and case series. These studies were limited to human patients, and no minimum follow-up was required.
This search generated 43 articles, which were divided among the panel so that each article was reviewed for relevancy by 2 members of the panel. Of these, 25 articles fit the search strategy, and they were rated by the panel methodologist (V.K.A.) according to the strength of the methodology and evidence. The methodologist used a subjective rating scale based on that developed by the Oxford Centre for Evidence-Based Medicine. 4 A level I rating was assigned to well-designed and well-conducted randomized clinical trials; a level II rating was assigned to well-designed case-control and cohort studies and poor-quality randomized trials; and a level III rating was assigned to case series, case reports, and poor-quality cohort and case-control studies. There were 2 level I studies, 2 level II studies, and 21 level III studies. Table 1 summarizes the 8 studies on enucleation on a pediatric population. Seven of 8 studies that addressed enucleation in children involved the placement of porous implants, and 1 study involved multiple types of implants.
Published Results

Pediatric Population
Heimann et al
5 (level III) studied 32 eyes of 28 patients (median age, 1.7 years) who underwent enucleation for retinoblastoma. These patients received silicone implants with polyester-urethane wrapping (n ¼ 13) or hydroxyapatite, silicone hydroxyapatite, or porous polyethylene (n ¼ 19), and they were followed up for a median of 22.4 months. Three cases of infection were identified, although the material type was not specified. The authors reported a 22% exposure rate (7 of 32 eyes); the exposure rate was 46% (6 of 13 eyes) for wrapped implants and 5% (1 of 19 eyes) for unwrapped implants where this complication developed. Motility outcomes were not noted in this study.
In a larger study, Shah et al 6 (level III) followed up 531 eyes of 525 patients (mean age, 3 years) who underwent enucleation and hydroxyapatite implant placement for intraocular tumors. They were followed up for a mean of 60 months. The authors used a scale to assess motility, and they rated the outcomes as excellent in 78%, fair in 19%, and poor in 3% of eyes. This study did not identify any cases of implant migration or extrusion, and it noted low rates for other complications (1% infection, 3% exposure, 2% conjunctival thinning). Choi et al 7 (level III) reviewed their experience with the use of polyethylene implants coated with a smooth surface anteriorly in 44 patients (mean age, 24.7 months) who underwent enucleation for retinoblastoma. These patients were followed up for a mean of 60.1 months, and using a subjective internal scale, all patients were found to have good socket motility after enucleation surgery. Furthermore, despite the relatively long mean follow-up period, the authors did not identify any cases of implant infection, exposure, or extrusion. However, less serious complications were relatively common after surgery, including conjunctival edema (34.1%), ptosis (18.2%), lower eyelid malposition (22.7%), conjunctival injection (15.9%), and conjunctival cyst formation (4.5%).
Similarly, Iordanidou and De Potter 8 (level III) reported the outcomes of wrapped polyethylene implants in a cohort of 36 patients (mean age, 4.6 years) who underwent enucleation for a variety of causes, including intraocular tumors, microphthalmos, Coats' disease, and trauma. They were followed up for a mean of 44 months. Although a standardized system was not used, the investigators subjectively rated motility as excellent in all cases and did not identify any cases of implant infection or extrusion. Three percent of patients demonstrated implant exposure and 3% demonstrated a pyogenic granuloma.
A smaller study, Marx et al 9 (level III) reported outcomes for 10 patients (mean age, 27 months) who underwent enucleation for retinoblastoma and received quasi-integrated polyethylene implants. These patients were followed up for a mean of 36 months, and no instances of implant migration, infection, or extrusion were identified, although the authors noted 1 exposure. The authors did not assess motility in this study. Kirzhner et al 10 (level III) used hydroxyapatite implants in 60 patients (mean age, 2.6 years) who underwent enucleation; 59 of these patients were enucleated for retinoblastoma. Forty-three received a coated implant and 17 received a wrapped implant. They were followed up for a median of 3.6 years, and no cases of implant migration or infection, socket contracture, or pyogenic granuloma were reported. The authors did not report motility outcomes. However, implant exposure occurred in 9.3% of patients with polymer-coated implants and in 17.7% of patients with wrapped implants. Additional surgery to address these issues was required in 9.3% of patients with polymer-coated implants and in 11.8% of patients with wrapped implants. Mourits et al 11 (level III) reviewed their experience with the use of hydroxyapatite (n ¼ 79) and PMMA (n ¼ 102) implants in 181 eyes that were enucleated for retinoblastoma. This study did not assess motility after enucleation. The rates of implant exposure or extrusion were 4.9% in patients who received acrylic implants and 12.7% in patients who received hydroxyapatite implants, although this difference was not statistically significant (P ¼ 0.06). Nolan et al 12 (level III) assessed 19 children (mean age, 24.3 months) who underwent enucleation with placement of a sclerawrapped hydroxyapatite implant. These patients were followed up for a mean of 84.2 months, and motility was not evaluated in this study. Seven patients (36.8%) demonstrated conjunctival erosion and 3 (15.7%) experienced implant exposure, but no infections were noted. Table 2 summarizes the 15 studies that address enucleation on an adult population. As in the literature on orbital implants in children, most studies of enucleation on adults used porous implants. Of the 4 studies that used nonporous implants, complication rates were reported, but the authors did not assess motility after enucleation.
Adult Population
Nonporous Implants. Madill and Maclean 16 (level III) followed up 10 patients (mean age, 46.6 years) for a mean of 14.5 years. The patients underwent enucleation for pain, buphthalmos, phthisis bulbi, and penetrating injury, and these surgeries involved a reverse sclera replacement technique. The authors used 3 coral and 7 acrylic implants. There were no cases of infection, exposure, or extrusion, but 1 patient who received a hydroxyapatite implant experienced an orbital hemorrhage. Wells and Harris 17 (level III) described their experience with direct fixation of the extraocular muscles to a silicone sphere in 75 patients (mean age, 54 years) who were followed up for a mean of 27 months. Although there were no implant infections in this group, 1 patient demonstrated an implant extrusion (1.3%) and 1 implant (1.3%) became exposed. Jongman et al 18 (level III) reviewed 179 patients (mean age, 60.9 years) for an average of 12.6 months after enucleation with placement of a sclera-wrapped acrylic implant. Three patients experienced complications: 1 demonstrated implant exposure, 1 demonstrated orbital cellulitis, and 1 experienced intractable chemosis (0.6% for each complication). Ten patients (5.6%) required ectropion repair and 9 patients (5.0%) demonstrated local irritation. Motility was not assessed specifically in this study. Tataru and Pop 19 (level III) reported their experience with 42 patients who underwent enucleation for choroidal melanoma and received PMMA implants that were covered with polyethylene terephthalate. The average follow-up duration was not specified, although the investigators noted that the patients were followed up for a "maximum of 15 years." An extrusion rate of 7.1% was reported. 20 (level III) followed 143 patients (mean age ¼ 43.4 years) who underwent enucleation in the setting of trauma and received hydroxyapatite implants, 77 of which were wrapped in donor sclera and 66 of which were unwrapped. Patients were followed for a mean of 37.2 months, and 8 (5.6%) developed an implant exposure (1.3% of wrapped implants, 10.6% of unwrapped implants). One implant extruded and 1 became infected. Motility was not reported in this study. Chao and Harbour 21 (level III) reported the outcomes of 139 patients who underwent enucleation for uveal melanoma and received hydroxyapatite (n ¼ 64) or polyethylene scleralwrapped implants (n ¼ 75). The patients with hydroxyapatite implants were followed up for a mean of 46.4 months, and the patients with polyethylene implants were followed up for 15 months. Motility was not assessed specifically, and complication rates were relatively low. One implant became exposed in the polyethylene group (1.3%), a cyst formed in 1 patient in each group (1.6% for the hydroxyapatite group, 1.3% for the polyethylene group), ptosis developed in 2 patients in each group (3.2% for the hydroxyapatite group, 2.6% for the polyethylene group), and 1 patient in each group demonstrated a volume deficit (1.6% for the hydroxyapatite group, 1.3% for the polyethylene group). Shields et al 22 (level III) placed polymer-coated hydroxyapatite implants in 126 patients (mean age, 43 years) and followed up these patients for a mean of 14 months. The indications for enucleation included uveal melanoma, retinoblastoma, pain, and neovascular glaucoma. Using a standardized subjective grading system, the authors reported good motility after enucleation in 94% of patients, fair motility in 5%, and poor motility in less than 2%. Furthermore, this study demonstrated an infection rate of less than 1%, an exposure rate of 2%, and an extrusion rate of 0%. Minor complications included conjunctival discharge in 6%, conjunctival thinning in less than 1%, pyogenic granuloma formation in less than 1%, and the development of a cyst in 2% of cases. Yoon et al 23 (level III) reported on 54 patients (mean age, 32 years) who underwent enucleation and scleral-wrapped hydroxyapatite implant placement for a variety of causes, including trauma, microphthalmos or congenital cataract, glaucoma, retinal detachment, and uveitis. Patients were followed up for a mean of 18 months. This study did not identify any cases of infection, exposure, or extrusion, but the authors reported a 2.6% incidence of conjunctival dehiscence, a 1.3% rate of cyst formation, and a 5.4% rate of conjunctival contracture. The authors did not assess motility.
Longer-term follow-up data yield results that are consistent with these outcomes. For a mean of 50 months, Jung et al 24 (level III) followed up 43 patients (mean age, 46.8 years) who underwent enucleation and placement of polyethylene implants. Indications for the surgeries included infection, glaucoma, corneal ulcer, ocular inflammation, and tumors. The authors did not identify any cases of subsequent infection, although exposure, ptosis, and sulcus deformity occurred in 9.3%, 20.9%, and 2.3% of cases, respectively. Gupta et al 14 (level II) followed up 19 patients (mean age, 63 years) who underwent enucleation for uveal melanoma. These patients received hydroxyapatite implants that were wrapped in Tutoplast (Katena Products, Inc., Denville, NJ) bovine pericardium, and they were followed up for a mean of 26 months (range, 22e30 months). Motility was not assessed in these patients, and the authors did not identify any cases of implant infection, exposure, or extrusion. One patient (5.3%) demonstrated eyelid laxity, and 1 patient (5.3%) demonstrated a conjunctival granuloma.
In a similar study, Gupta et al 25 (level III) used the same treatment strategy for 104 patients who had uveal melanoma and followed them up for 2.4 years. The authors reported that 3 patients (2.9%) demonstrated a wound dehiscence and 3 patients (2.9%) required eyelid tightening. Tari et al 15 (level II) documented their experience with meshcoated hydroxyapatite implants in 50 patients who were followed up for a mean of 13.2 months. Two patients (4%) demonstrated implant extrusion and 7 patients (14%) demonstrated superior sulcus deformities. The authors compared motility measurements of this group with those in a cohort of patients who underwent evisceration and found that enucleation with hydroxyapatite implantation resulted in inferior extrusion. Ma et al 26 (level III) retrospectively reviewed the results of placing porous polyethylene and bioglass implants in 170 sockets (mean age, 45.3 years). Seven sockets (4.1%) demonstrated an implant exposure; ectropion repair was required in 5 patients (2.9%) and volume augmentation was required in 3 patients (1.7%). One patient (0.6%) demonstrated an implant infection. Although motility was not assessed directly, the authors note that 161 sockets "did well." Perry and Tam 27 (level III) documented outcomes in 26 patients (mean age, 53.8 years) who received unwrapped implants (19 porous polyethylene, 5 PMMA, 2 hydroxyapatite) after enucleation. These patients were followed up for a mean of 17.1 months. Two patients experienced self-limited complications, including chemosis and giant papillary conjunctivitis. The authors did not assess motility, and no patient elected to undergo peg placement. Furthermore, no patient demonstrated extrusion, exposure, migration, or infection.
Porous and Nonporous Implants Compared. A few studies have compared porous and nonporous implants directly. Shome et al 13 (level I) reviewed their experience with 150 patients who underwent enucleation and received either a PMMA implant with muscle attachment (n ¼ 50), a PMMA implant placed via a myoconjunctival technique with muscle passed through Tenon's capsule and conjunctiva (n ¼ 50), or a porous polyethylene implant with scleral wrapping (n ¼ 50). The 3 groups were followed up for means of 16.4 months, 17.3 months, and 15.6 months, respectively. Using a standardized motility system, the authors concluded that implant motility was better in the PMMA-myoconjunctival and porous polyethylene groups, whereas prosthesis movement was best in the PMMAmyoconjunctival group. Twenty percent of patients demonstrated implant displacement and 12% of patients with a traditional PMMA implant demonstrated a sulcus deformity. The authors noted an 8% rate of exposure with porous polyethylene. Ho et al 28 (level I) used a different methodology to compare porous and nonporous implants among patients who underwent enucleation for uveal melanoma. After enucleation with either hydroxyapatite (n ¼ 139) or acrylic (n ¼ 142) implant placement, questionnaires were sent to patients and their ocularist. The number of patients in each group who withdrew from the study or did not complete the questionnaire increased over time. Subjective patient-reported motility was similar in both groups. Extrusion occurred in 1 patient (1.7%) who had a hydroxyapatite implant and in 3 patients (4.1%) who had an acrylic implant. There were no statistically significant differences between the 2 groups with respect to incidence of pain, discharge, infection, inability to wear the prosthesis, enophthalmos, and superior sulcus deformity.
In a retrospective study, Chuah et al 29 (level III) documented the outcomes of Asian patients who underwent enucleation with placement of a hydroxyapatite (n ¼ 21) or nonporous (n ¼ 38; 27 acrylic, 9 glass, 2 silicone) implant and were followed up for a mean of 2.7 years. Six patients who received hydroxyapatite implants (28.6%) and 3 patients who received nonintegrated implants (8.6%) demonstrated conjunctival dehiscences, and this difference was statistically significant. Implant extrusion, migration, and infection occurred only in patients with nonintegrated implants and were identified in 4, 4, and 3 patients, respectively. Migration was not specifically assessed in this study.
Conclusions
Porous implants carry the theoretical advantages of promoting fibrous ingrowth to facilitate implant stability and direct attachment of the recti, and also of allowing for placement of a peg system to couple the prosthesis directly to the orbital implant if desired. Most of the studies that were identified in the literature search used porous implants, and only a few studies directly compared porous and nonporous implants. The predominance of studies in the peer-reviewed literature involving outcomes from enucleations using porous implants is consistent with recent practice pattern reports that indicate that surgeons currently favor the use of this type of implant, 1, 30 even though unpegged porous implants have no apparent motility advantage over nonporous spheres. 2, 31 The common use of porous orbital implants may be based on the belief that fibrous ingrowth affords protection against migration. 17 However, migration also can be avoided by attaching muscles to the wrapping over a solid sphere of any type or by directly attaching the muscles to a solid silicone sphere. 17, 32 Both types of implants seem to be well tolerated, and in this review, the reported rates of major complications (i.e., infection and extrusion) generally were low for both types. Complication rates were assessed carefully in both porous and nonporous implant groups. Despite the overall favorable outcomes, in the studies identified in the literature search on the pediatric population, the rates of exposure differed according to the type of implant. Two studies 17, 19 reported the incidence of implant extrusion of nonporous implants, and rates ranging from 0% and 7.1% were documented over a several-year period. Exposure rates in the adult population generally were very low for porous implants, ranging from 0% to 5.6%, and extrusion rates ranged from 0% to 1.3%. The longer duration of follow-up in the studies that include patients who received nonporous implants may account for the higher rate in that group, because this complication may occur years after the initial surgery. 32 However, the rates of exposure and extrusion generally were comparable, suggesting that the choice of implant may not result in a dramatic difference in complication rates. Furthermore, the infection rates generally were low for nonporous implants (although 1 small study reported a rate of 7.9%) and less than 1% for porous implants. Of course, these outcomes must be considered in light of the inherent limitations of these studies.
Most of the studies that assessed the pediatric population did not evaluate postoperative motility at all, and only studies that involved porous implants addressed this outcome. Among the porous implants, the motility generally was very good.
Future Research
Given the recent trend among surgeons to use porous spheres after enucleation, a limited number of studies have assessed the impact of nonporous implants in this setting. However, nonporous implants remain viable options and carry acceptable outcomes with reasonable rates of complications. This literature search identified only 2 studies that met criteria for level I evidence from well-designed clinical trials to evaluate outcomes of orbital implants. More investigations that directly compare outcomes between the 2 types of implants among patients with similar conditions and from similar demographics would be a welcome addition to the literature to determine differences more decisively between implant varieties. Future studies should use rigorous methodology to explore the role that implant type has on outcomes of clinical relevance.
In a relatively small study, Heimann et al 5 documented exposure rates of 46% of wrapped nonporous implants, and other studies demonstrated a range of exposure rates of porous implants from 0% to 17.7%. Studies that involve a larger cohort of patients are needed to assess better the rate of exposure in nonporous implants.
Given the paucity of data on motility in patients who received nonporous implants and the absence of direct comparisons, definitive conclusions about the impact of implant material on motility cannot be made. Further studies would benefit from using standardized, objective scoring systems to evaluate motility outcomes after enucleation in children receiving nonporous implants.
To capture adequately the incidence of relatively rare complications and to draw meaningful conclusions about the effect of implant type on these complications, larger studies are likely required to power these investigations adequately. A large prospective study would help to provide greater insight. Certainly, additional research is required to assess the rates of complications among patients who receive porous and nonporous implants. Many of the studies referred to in this assessment focused on the first few years after enucleation. Given that patients who undergo this surgery may experience complications many years later, longer-term follow-up may identify greater differences in complication rates related to implant type.
